After the interest received by the previous editions and the excellent feed-back from all the attendants, the 13th edition of the ACT course will be organized by the ESACT (European Society of Animal Cell Technology) again in 2023. ESACT is presenting this activity as one more contribution to the community involved in the use of animal cells in Biotechnology and Biomedicine.
A limited number of grants, covering the course fee are provided by ESACT andACTIP. Applicants to the grants should indicate it in the course application, together with a motivation statement. Priority will be given to young PhD students from Academia but ACTIP will provide several grants for participants from industry, too.
The course comprises lectures covering the main topics of Animal Cell Technology:
Cell line development
Genomics and proteomics
Bioreactor scale-up, scale down and single use bioreactor
Integrated bioprocess for cell based vaccines
Economical aspects of ACT bioprocesses
Integrated bioprocess for protein production
Integrated bioprocess for stem cells
Industrial perspectives of ACT
The program has slots dedicated to the preparation and presentation of case studies by participants, and discussion groups with the lecturers.
Speakers to be confirmed: Terry Papoutsakis (University Delaware, USA), Manuel Carrondo and Paula Alves (iBET, Portugal), Hansjörg Hauser (HZI, Germany), Francesc Gòdia (UAB, Spain), Stefanos Grammatikos (UCB Pharma SA, Belgium) Nicole Borth (BOKU Vienna, Austria) and Anne Tolstrup (AbtBioConsult, Denmark).